Published online Jan 6, 2020. doi: 10.12998/wjcc.v8.i1.46
Peer-review started: October 28, 2019
First decision: November 13, 2019
Revised: November 19, 2019
Accepted: November 23, 2019
Article in press: November 23, 2019
Published online: January 6, 2020
Processing time: 70 Days and 20.9 Hours
Osteoarthritis is a multifactorial disease and its occurrence is positively related to age and is the leading cause of disability and pain.
There is currently no effective pharmacological strategy to prevent the development of the disease.
To evaluate the therapeutics of the compound Eucommia bone tonic granules for treating osteoarthritis and osteonecrosis.
Patients were separated into two treatment groups: the Eucommia-meloxicam group and the meloxicam group. In addition, the concentrations of bone-GLA protein, interleukin-17, recombinant human S100 calcium binding protein A12, Sphingosine 1-phosphate, cystatin C, creatinine, and hemoglobin were compared before and after treatment. The bone and joint necrosis test and osteonecrosis experiment were carried out to observe the total effective rate of the two groups.
The combination of Eucommia and meloxicam treatment resulted in improved pain relief and patient satisfaction.
The combination of Eucommia and meloxicam was an effective and safe drug in the treatment of osteoarthritis and osteonecrosis.
The patients with osteoarthritis and osteonecrosis will receive benefits from the latest innovations in drug therapies.